New therapies for chronic hepatitis B infection

Ting-Tsung Chang, Jidong D. Jia, Masao Omata, S. K. Yoon

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Conventional pharmacotherapeutic approaches to the management of chronic hepatitis B virus (HBV) infection are compromised by drug resistance and a failure to achieve sustained HBV DNA suppression. Low rates of seroconversion to hepatitis B e antigen-negative status and loss of hepatitis B surface antigen, as well as the potential for the development of adverse effects, are additional problems. Two agents, entecavir and the pegylated interferon (peginterferon) α-2a, have recently been added to the therapeutic armamentarium for the management of chronic hepatitis B (CHB). Data from clinical trials indicate that these newly licensed drugs may offer advantages over conventional treatments such as lamivudine and, possibly, adefovir. In addition, several novel agents in late-stage clinical development, specifically telbivudine and clevudine, have also shown encouraging results in patients with CHB infection. This review summarizes the current clinical experience with these new agents, focusing on data in Asian populations, and discusses the implications of the data for CHB management.

Original languageEnglish
Pages (from-to)30-37
Number of pages8
JournalLiver International
Volume26
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2006 Dec 1

Fingerprint

Chronic Hepatitis B
Infection
Hepatitis B virus
Lamivudine
Hepatitis B e Antigens
Virus Diseases
Therapeutics
Hepatitis B Surface Antigens
Drug Resistance
Interferons
Clinical Trials
DNA
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Chang, Ting-Tsung ; Jia, Jidong D. ; Omata, Masao ; Yoon, S. K. / New therapies for chronic hepatitis B infection. In: Liver International. 2006 ; Vol. 26, No. SUPPL. 2. pp. 30-37.
@article{1701e1e5a5484175988fd75ef15bca1b,
title = "New therapies for chronic hepatitis B infection",
abstract = "Conventional pharmacotherapeutic approaches to the management of chronic hepatitis B virus (HBV) infection are compromised by drug resistance and a failure to achieve sustained HBV DNA suppression. Low rates of seroconversion to hepatitis B e antigen-negative status and loss of hepatitis B surface antigen, as well as the potential for the development of adverse effects, are additional problems. Two agents, entecavir and the pegylated interferon (peginterferon) α-2a, have recently been added to the therapeutic armamentarium for the management of chronic hepatitis B (CHB). Data from clinical trials indicate that these newly licensed drugs may offer advantages over conventional treatments such as lamivudine and, possibly, adefovir. In addition, several novel agents in late-stage clinical development, specifically telbivudine and clevudine, have also shown encouraging results in patients with CHB infection. This review summarizes the current clinical experience with these new agents, focusing on data in Asian populations, and discusses the implications of the data for CHB management.",
author = "Ting-Tsung Chang and Jia, {Jidong D.} and Masao Omata and Yoon, {S. K.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1111/j.1478-3231.2006.01373.x",
language = "English",
volume = "26",
pages = "30--37",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "SUPPL. 2",

}

New therapies for chronic hepatitis B infection. / Chang, Ting-Tsung; Jia, Jidong D.; Omata, Masao; Yoon, S. K.

In: Liver International, Vol. 26, No. SUPPL. 2, 01.12.2006, p. 30-37.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New therapies for chronic hepatitis B infection

AU - Chang, Ting-Tsung

AU - Jia, Jidong D.

AU - Omata, Masao

AU - Yoon, S. K.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Conventional pharmacotherapeutic approaches to the management of chronic hepatitis B virus (HBV) infection are compromised by drug resistance and a failure to achieve sustained HBV DNA suppression. Low rates of seroconversion to hepatitis B e antigen-negative status and loss of hepatitis B surface antigen, as well as the potential for the development of adverse effects, are additional problems. Two agents, entecavir and the pegylated interferon (peginterferon) α-2a, have recently been added to the therapeutic armamentarium for the management of chronic hepatitis B (CHB). Data from clinical trials indicate that these newly licensed drugs may offer advantages over conventional treatments such as lamivudine and, possibly, adefovir. In addition, several novel agents in late-stage clinical development, specifically telbivudine and clevudine, have also shown encouraging results in patients with CHB infection. This review summarizes the current clinical experience with these new agents, focusing on data in Asian populations, and discusses the implications of the data for CHB management.

AB - Conventional pharmacotherapeutic approaches to the management of chronic hepatitis B virus (HBV) infection are compromised by drug resistance and a failure to achieve sustained HBV DNA suppression. Low rates of seroconversion to hepatitis B e antigen-negative status and loss of hepatitis B surface antigen, as well as the potential for the development of adverse effects, are additional problems. Two agents, entecavir and the pegylated interferon (peginterferon) α-2a, have recently been added to the therapeutic armamentarium for the management of chronic hepatitis B (CHB). Data from clinical trials indicate that these newly licensed drugs may offer advantages over conventional treatments such as lamivudine and, possibly, adefovir. In addition, several novel agents in late-stage clinical development, specifically telbivudine and clevudine, have also shown encouraging results in patients with CHB infection. This review summarizes the current clinical experience with these new agents, focusing on data in Asian populations, and discusses the implications of the data for CHB management.

UR - http://www.scopus.com/inward/record.url?scp=33750707232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750707232&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2006.01373.x

DO - 10.1111/j.1478-3231.2006.01373.x

M3 - Review article

AN - SCOPUS:33750707232

VL - 26

SP - 30

EP - 37

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - SUPPL. 2

ER -